
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

Medical and Health Services Network Service Provider

Recently, Qilu Pharmaceutical's tafamidis meglumine soft capsules (brand name: Shenyoumei®) exclusively launched on AliHealth.Qilu Pharmaceutical stated that,This product is the first tafamidis meglumine soft capsules approved for marketing in China,Used to delay peripheral nerve function impairment,for transthyretin amyloidosis polyneuropathyI Stage (ATTR-PN) to provide new treatment options for patients.

Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) is a rare hereditary, progressive diseaseCaused by abnormal transthyretin protein deposition, it can affect motor nerves, sensory nerves, autonomic nerves, as well as multiple organs such as the heart, kidneys, and eyes. As the disease progresses, patients' quality of life will be severely impacted; therefore, early identification and standardized treatment are crucial for delaying disease progression.
The newly launched tafamidis meglumine soft capsules belong to transthyretin (TTR) stabilizers, which can selectively bind to and stabilizeTTR, reducing abnormal protein deposition, thereby delaying disease progression. AsATTR-PNas a key therapeutic agent, the market launch of this first domestically produced generic version breaks the monopoly of single-source imports, further enriching clinical treatment options and promising more accessible medication regimens for patients to meet the needs of long-term standardized therapy.
In recent years, with the continuous improvement of public awareness of rare diseases, patients' demand for specialized and convenient pharmaceutical and healthcare services has also continued to grow.Qilu Pharmaceutical has long focused on unmet clinical needs, continuously advancing high-quality innovation and the research and development of high-level generic drugs. The approval of tafamidis meglumine soft capsules also demonstrates the company’s technological breakthroughs in the field of soft capsule formulations.
As"Launch Hub for Novel Specialty Drugs"Leveraging the supply and outreach capabilities of its digital pharmaceutical and healthcare service platform, AliHealth continuously introduces new drugs and steadily expands drug coverage in key areas such as rare diseases. By integrating online consultations, pharmacist-led medication guidance, and delivery services, AliHealth helps dispersed and underserved patients with rare diseases more easily access appropriate medications, thereby shortening the pathway for delivering high-quality medicines to those in need.
This joint launch of a new drug by both parties has further enriched the platform’s supply of medicines for rare diseases, demonstrating a proactive exploration of collaboration between the platform and pharmaceutical companies to promote equitable access to high-quality medical resources. In the future, AliHealth will continue to leverage its digital platform advantages, partner with more pharmaceutical enterprises, and continuously improve the drug supply and healthcare service systems for key disease areas, including rare diseases, oncology, and chronic diseases.
